SCHEMBL16368797

SCHEMBL16368797

COC(=O)C(C)(C)CCCCC(C)(C)C(=O)OCCOCCOC(=O)C(C)(C)CCCCC(C)(C)C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.47
CYP4A11 Q02928 2/20 0.47
THRB P10828 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.32
ACLY P53396 1/20 0.32
TSHR P16473 4/20 0.31
ALDH1A1 P00352 3/20 0.31
TP53 P04637 3/20 0.31
HIF1A Q16665 2/20 0.31
DGAT1 O75907 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
ELANE P08246 1/20 0.30
CYP3A4 P08684 2/20 0.30
ABCB11 O95342 1/20 0.30
ADRA2B P18089 1/20 0.30
OPRD1 P41143 1/20 0.30
SCN5A Q14524 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16368808 0.96 CYP4F2 (0.43) CYP4F2CYP4A11TSHRALDH1A1TP53
SCHEMBL16368798 0.92 CYP4F2 (0.38) CYP4F2CYP4A11TSHRALDH1A1TP53
SCHEMBL20375533 0.86 CYP4F2 (0.43) CYP4F2CYP4A11THRBPKMHTT
SCHEMBL17085271 0.85 CYP4F2 (0.47) CYP4F2CYP4A11THRBPKMHTT
SCHEMBL5527551 0.85 CYP4F2 (0.46) CYP4F2CYP4A11THRBPKMHTT
SCHEMBL6256870 0.85 CYP4F2 (0.42) CYP4F2CYP4A11THRBPKMHTT
SCHEMBL6258518 0.82 CYP4F2 (0.39) CYP4F2CYP4A11ACLYTSHRDGAT1
SCHEMBL6258085 0.82 DGAT1 (0.37) CYP4F2CYP4A11DGAT1ELANE
SCHEMBL17085273 0.81 CYP4F2 (0.43) CYP4F2CYP4A11THRBTSHRALDH1A1
SCHEMBL9481795 0.81 CYP4F2 (0.43) CYP4F2CYP4A11TSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2017-04-27 US disclosed
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2015-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA CYP4F2 2815/4885CYP4A11 1132/4885THRB 2491/4885
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA CYP4F2 2815/4885CYP4A11 1132/4885THRB 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.